Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $8.27 and traded as high as $12.18. Seres Therapeutics shares last traded at $11.36, with a volume of 107,170 shares changing hands.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on MCRB shares. Chardan Capital reaffirmed a "neutral" rating and set a $6.00 target price (up previously from $1.25) on shares of Seres Therapeutics in a research report on Thursday, May 8th. The Goldman Sachs Group dropped their target price on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a research report on Friday, March 14th. Finally, Wall Street Zen raised Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $73.67.
Read Our Latest Stock Report on MCRB
Seres Therapeutics Trading Down 8.6%
The stock has a market cap of $94.72 million, a price-to-earnings ratio of -2.36 and a beta of 2.75. The stock has a 50-day moving average price of $8.30 and a two-hundred day moving average price of $12.43.
Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($1.57). Research analysts predict that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current fiscal year.
Institutional Trading of Seres Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its position in Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 21,679 shares during the period. Invesco Ltd. lifted its position in Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 89,995 shares during the period. SBI Securities Co. Ltd. lifted its position in Seres Therapeutics by 221.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 48,013 shares during the period. Vontobel Holding Ltd. lifted its position in Seres Therapeutics by 15.7% during the 1st quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock worth $760,000 after acquiring an additional 147,671 shares during the period. Finally, Millennium Management LLC lifted its position in Seres Therapeutics by 77.2% during the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock worth $1,505,000 after acquiring an additional 788,762 shares during the period. Institutional investors and hedge funds own 59.34% of the company's stock.
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Featured Stories
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.